The Future of Precision Medicine and Genetic Testing in the Community
Lawrence D. Wagman, MD, FACS, executive medical director of St. Joseph’s Hospital, discusses the future of precision medicine and genetic testing in the community.<br />
Lawrence D. Wagman, MD, FACS, executive medical director of St. Joseph’s Hospital, discusses the future of precision medicine and genetic testing in the community.
Wagman says that he would like to see a separation between data that might be interesting in the future, from data that will have immediate impact on treatment or access to clinical trials. Real-world application remains of the upmost important to community oncologists who must integrate these protocols into their day-to-day routines.
Community physicians need to be more careful about explaining what genetic risk means to their patients, says Wagman. It is important that the patient understands the difference between a 1% risk and an 80% risk. He adds that he would also like to see more consistency in reporting from genetic testing companies.
Checkpoint Inhibitors Deliver Longer OS in PPP2R1A-Mutated Endometrial Cancer vs Wild-Type Disease
April 7th 2025Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed inactivating PPP2R1A mutations vs patients with wild-type PPP2R1A.
Read More
